Sonoma Pharmaceuticals, Inc. (SNOA)
After hours:
| Previous close | 4.3200 |
| Open | 3.8000 |
| Bid | 3.7100 x 800 |
| Ask | 3.8600 x 1000 |
| Day's range | 3.6800 - 4.1100 |
| 52-week range | 3.6800 - 13.3600 |
| Volume | |
| Avg. volume | 223,825 |
| Market cap | 11.802M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5700 |
| Earnings date | 14 Feb 2022 - 18 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
WOODSTOCK, Ga., January 20, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional distribution partner in the United States for dental care and expanded its oral and dental care li
- Business Wire
Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
WOODSTOCK, Ga., January 05, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually.
- Business Wire
Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
WOODSTOCK, Ga., November 15, 2021--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2021.
